Vimarsana
Biggest News Aggregation in the World

Page 2 - Robert Schumm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Robert Schumm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Robert Schumm Today - Breaking & Trending Today

ASCENSIA DIABETES CARE ANNOUNCES EUROPEAN APPROVAL OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM - Vimarsana News

ASCENSIA DIABETES CARE ANNOUNCES EUROPEAN APPROVAL OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM

/PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of CONTOUR® blood glucose monitoring (BGM) system portfolio and distributor of...

ASCENSIA DIABETES CARE LAUNCHES THE 6 MONTH EVERSENSE® E3 CONTINUOUS GLUCOSE MONITORING SYSTEM IN THE U.S. WITH THE NEW EVERSENSE PASS SAVINGS PROGRAM - Vimarsana News

ASCENSIA DIABETES CARE LAUNCHES THE 6 MONTH EVERSENSE® E3 CONTINUOUS GLUCOSE MONITORING SYSTEM IN THE U.S. WITH THE NEW EVERSENSE PASS SAVINGS PROGRAM

/PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that it has launched the next-generation Eversense® E3 Continuous Glucose...

Senseonics' long-lasting continuous glucose monitor receives FDA approval - Vimarsana News

Senseonics' long-lasting continuous glucose monitor receives FDA approval

Senseonics' FDA-approved CGM has a sensor that lasts six months, a first for any CGM. Other competing solutions from Medtronic and Dexcom last anywhere between three to 10 days.

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS - Vimarsana News

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS

/PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received...

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS - Vimarsana News

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS

/PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received...